Nanobiotix: Difference between revisions

Latest revision as of 10:46, 15 February 2025

Nanobiotix[edit]

Nanobiotix logo

Nanobiotix is a nanomedicine company that focuses on the development of nanoparticles for cancer treatment. The company is known for its innovative approach to enhancing the efficacy of radiotherapy using its proprietary technology.

History[edit]

Nanobiotix was founded in 2003 and is headquartered in Paris, France. The company was established with the aim of leveraging nanotechnology to improve cancer treatment outcomes. Over the years, Nanobiotix has developed a range of products that utilize nanoparticles to enhance the effects of traditional cancer therapies.

Technology[edit]

The core technology of Nanobiotix involves the use of nanoparticles to increase the effectiveness of radiotherapy. These nanoparticles are designed to accumulate in tumor tissues and amplify the radiation dose received by the cancer cells, thereby increasing the likelihood of destroying the tumor while minimizing damage to surrounding healthy tissues.

Nanoparticles in Radiotherapy[edit]

Nanobiotix's nanoparticles are engineered to interact with X-rays used in radiotherapy. When these nanoparticles are exposed to radiation, they produce secondary electrons that cause additional damage to the cancer cells. This process enhances the therapeutic index of radiotherapy, potentially allowing for lower doses of radiation to achieve the same or better therapeutic outcomes.

Products[edit]

Nanobiotix has developed several products based on its nanoparticle technology. The most notable product is NBTXR3, which is designed to be injected directly into tumors. NBTXR3 is currently being evaluated in clinical trials for various types of cancer, including head and neck cancer, liver cancer, and prostate cancer.

Clinical Trials[edit]

Nanobiotix is actively involved in clinical trials to assess the safety and efficacy of its products. These trials are conducted in collaboration with leading cancer research centers and hospitals around the world. The results of these trials will determine the future applications of Nanobiotix's technology in cancer treatment.

Future Directions[edit]

The future of Nanobiotix lies in expanding the applications of its nanoparticle technology beyond radiotherapy. The company is exploring the potential of its technology in combination with other cancer treatments, such as immunotherapy and chemotherapy.

Related pages[edit]

@@ Line 1: / Line 1: @@
-'''Nanobiotix''' is a leading company in the field of [[nanotechnology]] applied to [[medicine]], specifically focusing on the development of novel [[nanoparticle]] therapies for the treatment of [[cancer]]. The company's innovative approach combines the physical properties of nanoparticles with traditional cancer treatments to enhance their efficacy and reduce side effects. Nanobiotix's flagship product, NBTXR3, is a first-in-class radio-enhancer nanoparticle designed to increase the effectiveness of [[radiotherapy]] in various types of cancer.
+== Nanobiotix ==
-==Overview==
+[[File:Nanobiotix_Logo.jpg|thumb|right|Nanobiotix logo]]
-Nanobiotix was founded with the goal of leveraging nanotechnology to create better therapeutic options for cancer patients. The company's research and development efforts are centered around nanoparticles that can be activated by external stimuli, such as radiation, to induce tumor cell death without harming surrounding healthy tissues. This technology represents a significant advancement in oncology, offering the potential for more targeted and effective cancer treatments.
-==NBTXR3==
+'''Nanobiotix''' is a [[nanomedicine]] company that focuses on the development of [[nanoparticles]] for [[cancer]] treatment. The company is known for its innovative approach to enhancing the efficacy of [[radiotherapy]] using its proprietary technology.
-NBTXR3, Nanobiotix's leading product, is composed of hafnium oxide nanoparticles. When injected directly into a tumor and exposed to radiation, NBTXR3 nanoparticles absorb the radiation and emit higher energy levels within the tumor. This process enhances the local destruction of cancer cells while minimizing damage to adjacent healthy cells. NBTXR3 has shown promise in clinical trials for treating various cancers, including [[soft tissue sarcoma]], [[head and neck cancer]], and [[liver cancer]].
-==Clinical Trials==
+=== History ===
-Nanobiotix has conducted several [[clinical trial]]s to evaluate the safety and efficacy of NBTXR3. These trials have demonstrated that NBTXR3, in combination with radiotherapy, can significantly improve treatment outcomes in cancer patients. The company continues to explore the potential of NBTXR3 in other cancer types and in combination with other therapeutic modalities, such as [[immunotherapy]].
+Nanobiotix was founded in 2003 and is headquartered in [[Paris]], [[France]]. The company was established with the aim of leveraging nanotechnology to improve cancer treatment outcomes. Over the years, Nanobiotix has developed a range of products that utilize nanoparticles to enhance the effects of traditional cancer therapies.
-==Future Directions==
+=== Technology ===
-The success of NBTXR3 has positioned Nanobiotix as a pioneer in the field of nanomedicine for cancer treatment. The company is committed to furthering the development of its nanoparticle technology to address a wider range of cancers and to explore its potential in other medical applications beyond oncology. With ongoing research and development, Nanobiotix aims to revolutionize cancer treatment and improve the quality of life for patients worldwide.
+The core technology of Nanobiotix involves the use of [[nanoparticles]] to increase the effectiveness of [[radiotherapy]]. These nanoparticles are designed to accumulate in tumor tissues and amplify the radiation dose received by the cancer cells, thereby increasing the likelihood of destroying the tumor while minimizing damage to surrounding healthy tissues.
-==See Also==
+==== Nanoparticles in Radiotherapy ====
-* [[Nanotechnology]]
+Nanobiotix's nanoparticles are engineered to interact with [[X-rays]] used in radiotherapy. When these nanoparticles are exposed to radiation, they produce secondary electrons that cause additional damage to the cancer cells. This process enhances the [[therapeutic index]] of radiotherapy, potentially allowing for lower doses of radiation to achieve the same or better therapeutic outcomes.
-* [[Cancer]]
+=== Products ===
+Nanobiotix has developed several products based on its nanoparticle technology. The most notable product is NBTXR3, which is designed to be injected directly into tumors. NBTXR3 is currently being evaluated in clinical trials for various types of cancer, including [[head and neck cancer]], [[liver cancer]], and [[prostate cancer]].
+=== Clinical Trials ===
+Nanobiotix is actively involved in clinical trials to assess the safety and efficacy of its products. These trials are conducted in collaboration with leading cancer research centers and hospitals around the world. The results of these trials will determine the future applications of Nanobiotix's technology in cancer treatment.
+=== Future Directions ===
+The future of Nanobiotix lies in expanding the applications of its nanoparticle technology beyond radiotherapy. The company is exploring the potential of its technology in combination with other cancer treatments, such as [[immunotherapy]] and [[chemotherapy]].
+== Related pages ==
+* [[Nanomedicine]]
 * [[Radiotherapy]]
-* [[Clinical trial]]
+* [[Cancer treatment]]
-* [[Immunotherapy]]
+* [[Nanoparticles]]
-[[Category:Biotechnology companies]]
+[[Category:Nanomedicine]]
-[[Category:Nanotechnology]]
 [[Category:Cancer treatment]]
+[[Category:Companies of France]]
-{{cancer-stub}}